NCT02728947已完成1 期
A Single Group and Open-label Study to Evaluate Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 3
- 主要终点
- CMax of ROTIGOTINE
研究概览
简要总结
To study the profile of Neupro patch administrated at 2 mg, 4 mg, 6 mg and 8 mg/day weekly in patients with early-stage Parkinson's disease
详细描述
A single group and open-label study to evaluate pharmacokinetic profile of Neupro patch administrated at 2 mg, 4 mg, 6 mg and 8 mg/day weekly in patients with early-stage Parkinson's disease
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient who is capable of giving informed consent and complying with study procedures
- •Patient who has Idiopathic Parkinson's Disease defined by the cardinal sign, bradykinesia, plus the presence of at least 1 of the following: resting tremor, rigidity, or impairment of postural reflexes, and without any other known or suspected cause of Parkinsonism
- •Patient who is Hoehn & Yahr stage less than or equal to 3
- •Patient who is male or female aged greater than or equal to 18 years at Screening
- •Patient who has a Mini Mental State Examination (MMSE) score of greater than or equal to 25
- •Patient who has a Unified Parkinson's Disease Rating Scale (UPDRS) motor score (Part III) of greater than or equal to 10 but less then or equal to 30 at Screening
排除标准
- •Patient who has atypical Parkinson's syndrome(s) due to drugs (e.g., metoclopramide, flunarizine), metabolic neurogenetic disorders (e.g., Wilson's Disease), encephalitis, cerebrovascular disease, or degenerative disease (e.g., progressive Supranuclear Palsy)
- •Patient who has a history of pallidotomy, thalamotomy, deep brain stimulation, or fetal tissue transplant
- •Patient who has dementia, active psychosis or hallucinations, or clinically significant depression
- •Patient who has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response ("Yes") to either Question 4 or Question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) at Screening
- •Patient who has a history of symptomatic orthostatic hypotension with a decrease of less than or equal to 20 mmHg in systolic blood pressure (SBP) or great than or equal to 10 mmHg in diastolic blood pressure when changing from supine to standing position after having been at supine position for at least 5 minutes within 28 days prior to the Screening Visit, or SBP less than 105 mmHg at study entry, or reports clinical signs of clinically significant orthostatic hypotension within 28 days prior to the Screening Visit.
- •Patient who is receiving therapy with a dopamine agonist either concurrently or has done so within 28 days prior to the Screening
- •Patient who is receiving therapy with 1 of the following drugs either concurrently or within 28 days prior to screening: MAO-B inhibitors, DA releasing agents, DA modulating agent, DA antagonists, neuroleptics, or other medications that may interact with DA function.
- •Patient who is currently receiving central nervous system active therapy (e.g., sedatives, hypnotics, antidepressants, anxiolytics), unless the dose has been stable for at least 28 days prior to Screening Visit and is likely to remain stable for the duration of the study. Patients should not take those medications within 8 hours prior to clinical visits
- •Patient who has a current diagnosis of epilepsy, has a history of seizures as an adult, has a history of stroke, or has had a transient ischemic attack within 1 year prior to Screening
- •Patient who has a history of known intolerance/hypersensitivity to non-dopaminegic antiemetics, such as domperidone, ondansetron, tropisetron, and glycopyrrolate
- •Patient who has any other clinically relevant hepatic, renal and cardiac dysfunction, or other medical condition or laboratory abnormality including abnormal plasma magnesium level, which would in the judgment of the investigator, interfere with the patient's ability to participate in the study
- •Patient who has a history of significant skin hypersensitivity to adhesive or other transdermal preparations or recent unresolved contact Dermatitis
- •Patient with C-reactive protein levels of 2x of upper limit of normal range
- •Female patient who is pregnant or is breastfeeding or is of childbearing potential without adequate contraception.
- •Patient with a positive finding in drug screening test or alcohol test
研究组 & 干预措施
2mg
Active Comparator
1 week on 2mg/24 hr patch
干预措施: ROTIGOTINE (Drug)
4mg
Active Comparator
1 week on 4mg/24hr patch
干预措施: ROTIGOTINE (Drug)
6mg
Active Comparator
1 week on 6mg/24hr patch
干预措施: ROTIGOTINE (Drug)
8mg
Active Comparator
1 week on 8mg/24hr patch
干预措施: ROTIGOTINE (Drug)
结局指标
主要结局
CMax of ROTIGOTINE
时间窗: 38 Days
PK parameters Cmax-ss
次要结局
未报告次要终点
研究者
研究点 (3)
Loading locations...
相似试验
进行中（未招募）
1 期
A pharmacokinetic study to see the effect of Zevtera, a new infusion antibiotic, in babies younger than or equal 3 months.EUCTR2013-004614-18-LTBasilea Pharmaceutica International Ltd.45
进行中（未招募）
不适用
A Study to Evaluate the Pharmacokinetics and Safety of Doripenem in Children and Adolescents with Cystic FibrosisCystic fibrosisEUCTR2015-001225-16-Outside-EU/EEAJohnson & Johnson Pharmaceutical Research & Development L.L.C22
进行中（未招募）
1 期
An Open-Label Study to Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants (Term and Preterm), Less Than 12 Weeks Chronological Age Protocol DORI-PED-1003; Phase 1hospitalized but medically stable infants (term and preterm), <12 weeks CA, who have documented, presumed to have, or are at risk for bacterial infection(s) and are undergoing treatment with i.v. antibiotics.MedDRA version: 12.0 Level: LLT Classification code 10004044 Term: Bacterial infection NOSEUCTR2009-014387-20-GBJanssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium52
进行中（未招募）
1 期
A pharmacokinetic study to see the effect of Zevtera, a new infusion antibiotic, in babies younger than or equal 3 months.EUCTR2013-004614-18-LVBasilea Pharmaceutica International Ltd.45
进行中（未招募）
1 期
A pharmacokinetic study to see the effect of Zevtera, a new infusion antibiotic, in babies younger than or equal 3 months.EUCTR2013-004614-18-PLBasilea Pharmaceutica International Ltd.15